Nothing Special   »   [go: up one dir, main page]
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression

Oncogene volume 26, pages 158–163 (2007)Cite this article

Abstract

In sporadic colorectal cancer (CRC), KRAS are alternative to BRAF mutations and occur, respectively, in 30 and 10% of cases. Few reports addressed the association between KRAS–BRAF mutations and tumour progression specifically in sporadic microsatellite-stable (MSS) CRC. We screened KRAS and BRAF in 250 MSS primary CRC and 45 lymph node (LN) metastases and analysed the pathological features of the cases to understand the involvement of KRAS–BRAF activation in progression and metastasis. Forty-five per cent of primary MSS CRCs carried mutations in at least one of these genes and mutations were associated with wall invasion (P=0.02), presence and number of LN metastases (P=0.02 and P=0.03, respectively), distant metastases (P=0.004) and advanced stage (P=0.01). We demonstrated that KRAS and BRAF are alternative events in Tis and T1 MSS CRC and, KRAS rather than BRAF mutations, contributed to the progression of MSS CRC. The frequency of KRAS and/or BRAF mutations was higher in LN metastases than in primary carcinomas (P=0.0002). Mutated LN metastases displayed KRAS associated or not with BRAF mutations. BRAF mutations were never present as a single event. Concomitant KRAS and BRAF mutations increased along progression of MSS CRCs, suggesting that activation of both genes is likely to harbour a synergistic effect.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Al-Mulla F, Going JJ, Sowden ET, Winter A, Pickford IR, Birnie GD. (1998). Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 185: 130–138.

    Article  CAS  Google Scholar 

  • Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ et al. (2001). Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85: 692–696.

    Article  CAS  Google Scholar 

  • Bernards R, Weinberg RA . (2002). A progression puzzle. Nature 418: 823.

    Article  CAS  Google Scholar 

  • Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM et al. (2003). K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703–710.

    Article  CAS  Google Scholar 

  • Campbell PM, Der CJ . (2004). Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 14: 105–114.

    Article  CAS  Google Scholar 

  • Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO et al. (2004). Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 10: 3448–3456.

    Article  CAS  Google Scholar 

  • Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002). Mutations of the BRAF gene in human cancer. Nature 417: 949–954.

    Article  CAS  Google Scholar 

  • Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA et al. (2004). BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10: 191–195.

    Article  CAS  Google Scholar 

  • Domingo E, Espin E, Armengol M, Oliveira C, Pinto M, Duval A et al. (2004). Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer. Genes Chrom Cancer 39: 138–142.

    Article  CAS  Google Scholar 

  • Fearon ER, Vogelstein B . (1990). A genetic model for colorectal tumorigenesis. Cell 61: 759–767.

    Article  CAS  Google Scholar 

  • Finkelstein SD, Sayegh R, Christensen S, Swalsky PA . (1993). Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type Cancer. Cancer 71: 3827–3838.

    Article  CAS  Google Scholar 

  • Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P . (2004). Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25: 527–533.

    Article  CAS  Google Scholar 

  • Fugimoto K, Sheng H, Shao J, Beauchamp RD . (2001). Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells. Exp Cell Res 266: 239–249.

    Article  Google Scholar 

  • Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA . (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198–5202.

    CAS  PubMed  Google Scholar 

  • Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813–822.

    Article  CAS  Google Scholar 

  • Hughes PE, Renshaw MW, Pfaff M, Forsyth J, Keivens VM, Schwartz MA et al. (1997). Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 88: 521–530.

    Article  CAS  Google Scholar 

  • Ikehara N, Semba S, Sakashita M, Aoyama N, Kasuga M, Yokozaki H . (2005). BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. Int J Cancer 115: 943–950.

    Article  CAS  Google Scholar 

  • Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M et al. (2005). Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 97: 981–989.

    Article  CAS  Google Scholar 

  • Kerkhoff E, Rapp UR . (1998). High-intensity Raf signals convert mitotic cell cycling into cellular growth. Cancer Res 58: 1636–1640.

    CAS  PubMed  Google Scholar 

  • Koinuma K, Shitoh K, Miyakura Y, Furukawa T, Yamashita Y, Ota J et al. (2004). Mutations of BRAF are associated with extensive MLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer 108: 237–242.

    Article  CAS  Google Scholar 

  • Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S et al. (2003). BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9: 3362–3368.

    CAS  PubMed  Google Scholar 

  • Liao J, Wolfman JC, Wolfman A . (2003). K-ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts. J Biol Chem 278: 31871–31878.

    Article  CAS  Google Scholar 

  • Lipton L, Halford SE, Johnson V, Novelli MR, Jones A, Cummings C et al. (2003). Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway. Cancer Res 63: 7595–7599.

    CAS  PubMed  Google Scholar 

  • Lubomierski N, Plotz G, Wormek M, Engels K, Kriener S, Trojan J et al. (2005). BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer 104: 952–961.

    Article  CAS  Google Scholar 

  • Marshall M . (1995). Interactions between Ras and Raf: key regulatory proteins in cellular transformation. Mol Reprod Dev 42: 493–499.

    Article  CAS  Google Scholar 

  • Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G et al. (2005). The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115: 1068–1081.

    Article  CAS  Google Scholar 

  • Moerkerk P, Arends JW, van Driel M, de Bruine A, de Goeij A, ten Kate J . (1994). Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 54: 3376–3378.

    CAS  PubMed  Google Scholar 

  • Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K et al. (2004). Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 22: 4584–4594.

    Article  CAS  Google Scholar 

  • Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E et al. (2003). RAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 22: 9192–9196.

    Article  CAS  Google Scholar 

  • Oliveira C, Velho S, Domingo E, Preto A, Hofstra RM, Hamelin R et al. (2005). Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene 24: 7630–7634.

    Article  CAS  Google Scholar 

  • Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A et al. (2004). Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 13: 2303–2311.

    Article  CAS  Google Scholar 

  • Pollock CB, Shirasawa S, Sasazuki T, Kolch W, Dhillon AS . (2005). Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res 65: 1244–1250.

    Article  CAS  Google Scholar 

  • Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003). High frequency of BRAF mutations in nevi. Nat Genet 33: 19–20.

    Article  CAS  Google Scholar 

  • Pretlow TP . (1995). Aberrant crypt foci and K-ras mutations: earliest recognized players or innocent bystanders in colon carcinogenesis? Gastroenterology 108: 600–603.

    Article  CAS  Google Scholar 

  • Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE . (2002). Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934.

    Article  CAS  Google Scholar 

  • Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA et al. (2005). Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65: 6063–6069.

    Article  CAS  Google Scholar 

  • Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ et al. (2003). From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100: 7737–7742.

    Article  CAS  Google Scholar 

  • Schramm K, Krause K, Bittroff-Leben A, Goldin-Lang P, Thiel E, Kreuser ED . (2000). Activated K-ras is involved in regulation of integrin expression in human colon carcinoma cells. Int J Cancer 87: 155–164.

    Article  CAS  Google Scholar 

  • Sewing A, Wiseman B, Lloyd AC, Land H . (1997). High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 17: 5588–5597.

    Article  CAS  Google Scholar 

  • Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A et al. (2006). BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358–362.

    Article  CAS  Google Scholar 

  • Span M, Moerkerk PT, De Goeij AF, Arends JW . (1996). A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 69: 241–245.

    Article  CAS  Google Scholar 

  • Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K et al. (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23: 6031–6039.

    Article  CAS  Google Scholar 

  • Thiery JP . (2002). Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442–454.

    Article  CAS  Google Scholar 

  • Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J et al. (2004). Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96: 261–268.

    Article  CAS  Google Scholar 

  • Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz Jr S et al. (2005). The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41: 1649–1654.

    Article  CAS  Google Scholar 

  • Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al. (1988). Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525–532.

    Article  CAS  Google Scholar 

  • Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA et al. (2003). BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 63: 5209–5212.

    CAS  PubMed  Google Scholar 

  • Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M . (1997). Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17: 5598–5611.

    Article  CAS  Google Scholar 

  • Yamamoto H, Itoh F, Senota A, Adachi Y, Yoshimoto M, Endoh T et al. (1995). Expression of matrix metalloproteinase matrilysin (MMP-7) was induced by activated Ki-ras via AP-1 activation in SW1417 colon cancer cells. J Clin Lab Anal 9: 297–301.

    Article  CAS  Google Scholar 

  • Yan Z, Chen M, Perucho M, Friedman E . (1997). Oncogenic Ki-ras but not oncogenic Ha-ras blocks integrin beta1-chain maturation in colon epithelial cells. J Biol Chem 272: 30928–30936.

    Article  CAS  Google Scholar 

  • Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rutten A et al. (2003). Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121: 1160–1162.

    Article  CAS  Google Scholar 

  • Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C et al. (2002). Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62: 6451–6455.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Supported by Grants: Portuguese Fundação para a Ciência e Tecnologia (POCTI/SAU-OBS/56921/2004; REEQ/218/SAL/2005); Novartis- Portugal; Spanish Fondo de Investigaciones Sanitarias (FIS 05/0304); SV, CM, AF and AP were supported by fellowships from the Portuguese Fundação para a Ciência e Tecnologia.

Author information

Authors and Affiliations

  1. Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal

    C Oliveira, S Velho, C Moutinho, A Ferreira, A Preto, J C Machado, F Carneiro & R Seruca

  2. Molecular Oncology and Aging Research, Centre d'Investigacions en Bioquimica i Biologia Molecular (CIBBIM), Hospital Universitari Vall d'Hebron, Barcelona, Spain

    E Domingo & S Schwartz Jr

  3. Pathology Department, Hospital de S. João, Porto, Portugal

    A F Capelinha & F Carneiro

  4. INSERM U762 CEPH, INSERM, Paris, France

    A Duval & R Hamelin

  5. Faculty of Medicine, University of Porto, Porto, Portugal

    J C Machado, F Carneiro & R Seruca

Authors
  1. C Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Velho
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Moutinho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Preto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Domingo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A F Capelinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Duval
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Hamelin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J C Machado
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S Schwartz Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. F Carneiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R Seruca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Seruca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oliveira, C., Velho, S., Moutinho, C. et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26, 158–163 (2007). https://doi.org/10.1038/sj.onc.1209758

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209758

Keywords

This article is cited by

Search

Advanced search

Quick links